Author

H. Liu

Institutions: Agios Pharmaceuticals (United States), Chonnam National University Hwasun Hospital

Observed institutions: Agios Pharmaceuticals (United States), Chonnam National University Hwasun Hospital

OpenAlex ID: A5055597293

Very Low-Dose Decitabine is Effective in Treating Intermediate or High Risk Myelodysplastic Syndrome

2017 · H. Li, L. Wang, et al. · Leukemia Research · 2

Ps1337 Ivosidenib (ag‐120) Induces Durable Remissions and Transfusion Independence in Patients With Idh1‐mutant Relapsed/refractory Myelodysplastic Syndrome in a Phase 1 Dose Escalation and Expansion Study

2019 · J.M. Foran, C.D. DiNardo, et al. · HemaSphere

Works count: 2

Citation count: 2

H-index: 1

I10-index: